About Company
- Overview
- Information
- Review

Doc Generici
Italy
1996 (29 Years)
Last online: No recent activity
No Review
Not enough to calculate score
Provided by TrustFinance
Verification on TrustFinance
0.00
Traffic & Engagement
2.67
This company no score yet, be the first to review
Provided by TrustFinance
Security Information
What are the differences in regulations for each
License
A Grade License
Issued by globally renowned regulators, these licenses ensure the highest trader protection through strict compliance, fund segregation, insurance, and regular audits. Dispute resolution and adherence to AML/CTF standards further enhance security.
B Grade License
Granted by respected regional regulators, these licenses offer robust safety measures such as fund segregation, financial reporting, and compensation schemes. Though slightly less strict than Tier 1, they provide dependable regional protection.
C Grade License
Issued by regulators in emerging markets, these licenses offer basic protections such as minimum capital requirements and AML policies. Oversight is less stringent, so traders should exercise caution and verify safety measures.
D Grade License
From jurisdictions with minimal oversight, these licenses often lack key protections like fund segregation and insurance. While attractive for operational flexibility, they pose higher risks to traders.
Company Information
Get to know Doc Generici
Company Information
Get to know Doc Generici
DOC Generici was founded in 1996 following the passing of law 425 of 8 August that year, which approved the use of equivalent medicines. The company was created by the joint efforts of three pharmaceutical groups: Chiesi Farmaceutici, Zambon and the Canadian group Apotex, market leader in America in the production and distribution of equivalent medicines. Distribution started for real in 2001 when, following approval of law 405 of 16 November of that year, pharmacists became obliged to provide an equivalent medicine with the lowest price amongst those available on the normal regional distributive network, whenever a doctor prescribes a medicine without specifying that it is not to be substituted. Between 1996 and 2001 DOC Generici laid down the managerial, organizational and manufacturing foundations that enabled it to be among the first to enter the equivalent medicines market. On July 1st 2013 DOC Generici was acquired by Charterhouse Capital Partners LLP, a British Private Equity Fund and one of Europe's leading Private Equity Firms. This is the first investment in Italy by this large and historical Fund. The acquisition will allow DOC Generici to keep its independence and to continue its investment in the key objectives of its success: endorse Europe and especially Italy for manufacturing of generic medicinal products, prevent speculation on quality in favor of cost and keep a high level of communication.
Industry
- Financial BankingPRIMARY
Contact
-
-
-
-
Social
Company hasn't updated its information.
Users who look Doc Generici also look…
Reviews
Social Scout
See what Social Scout found of Doc Generici
Provided by TrustFinance AI Analysis
Doc Generici Reviews
Reviews
Total 0
AI Review analysis
Let’s TrustFinance AI Summarize all the reviews for you.
Provided by TrustFinance AI Analysis
Filter
5 Star
4 Star
3 Star
2 Star
1 Star
Sort by
AI Review analysis
Let’s TrustFinance AI Summarize all the reviews for you.
Provided by TrustFinance AI Analysis



